KRSA
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -343.24 | $0 | -$47M |
| 2026 Q2 | -0.35 | $0 | -$1M |
| 2026 Q1 | -0.76 | $0 | -$1M |
| 2025 Q4 | -0.16 | $1M | -$2M |
| 2025 Q3 | -0.19 | $875,000 | -$264,000 |
| 2025 Q2 | -0.11 | $93,000 | -$503,000 |
| 2025 Q1 |
| -0.56 |
| $81,000 |
| -$968,000 |
| 2024 Q4 | 0.14 | $2M | $360,000 |